The state of Connecticut is trying a novel approach to reducing its drug spending for the Opioid Dependence drug class of Buprenorphine. Connecticut would like to force all insurance companies, includ

The state of Connecticut is trying a novel approach to reducing its drug spending for the Opioid Dependence drug class of Buprenorphine. Connecticut would like to force all insurance companies, including Medicaid, to purchase Buprenorphine through one manufacturer unless there is a medical reason that it is not possible. Indivior, the maker of a Buprenorphine brand name drug called Suboxone, has stated that if they become the sole manufacturer and supplier to Connecticut, they will sell their product for 10% less per unit than the average generic cost. They have asked you to figure out how much money it would save the state’s healthcare system.